AG14361

328543-09-5

C19H20N4O

DMSO : >= 32 mg/mL (99.88 mM)

Epigenetics; Cell Cycle/DNA Damage

AG14361 is a potent PARP-1 inhibitor, with a K_i of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC₅₀s are 29 nM and 14 nM, respectively. IC50 & Target: Ki: < 5 nM (PARP-1)^[1]
IC50: 29 nM (PARP-1, in permeabilized SW620 cells), 14 nM (PARP-1, in intact SW620 cells)^[1] In Vitro: AG14361 is a potent PARP-1 inhibitor, with a K_i of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC₅₀s are 29 nM and 14 nM, respectively. AG14361 inhibits the proliferation of human cancer cells, such as A549, LoVo, and SW620 cells, with GI₅₀s of 14 uM, 11.2 uM and 20 uM, respectively. Furthermore, AG14361 in combination with NSC 362856 markedly reduces the GI₅₀ value of NSC 362856 in LoVo and A549 cells, but does not exert such an effect in SW620 cells^[1]. AG14361 suppresses breast cancer cells with IC₅₀s of 17 uM and 25 uM for 92 J-wt-BRCA1 and 92 J-sh-BRCA1 cells, respectively. AG14361 induces caspase 3/7 activation and cell cycle abnormalities, and also inhibits NF-kappaB signaling^[2]. AG14361 (0.4 uM) enhances the growth-inhibitory and cytotoxic effects of topoisomerase I poisons, with no obvious effect on the formation and reversal of cleavable complexes, and increases the persistence of camptothecin-induced DNA single-strand breaks^[3]. In Vivo: AG14361 (5 and 15 mg/kg, i.p.) has no toxicity and does not inhibit the growth of tumor. However, AG14361 markedly enhances NSC 362856 activity against LoVo xenografts and delays tumor growth when combined with NSC 362856. AG14361 (15 mg/kg, i.p.) treatment before irradiation dramaticly increases the sensitivity to radiation therapy of mice bearing LoVo xenografts^[1]. AG14361 (30 mg/kg) synergizes lestaurtinib activity on inhibiting breast cancer tumors in allografts^[2].